UFP Technologies, Inc.

UFP Technologies, Inc. (UFPT) Market Cap

UFP Technologies, Inc. has a market capitalization of $1.56B.

Financials based on reported quarter end 2025-12-31

Price: $202.38

โ–ฒ 8.34 (4.30%)

Market Cap: 1.56B

NASDAQ ยท time unavailable

CEO: R. Jeffrey Bailly

Sector: Healthcare

Industry: Medical - Devices

IPO Date: 1993-12-17

Website: https://www.ufpt.com

UFP Technologies, Inc. (UFPT) - Company Information

Market Cap: 1.56B ยท Sector: Healthcare

UFP Technologies, Inc. designs and custom manufactures components, subassemblies, products, and packaging utilizing specialized foams, films, and plastics primarily for the medical market. Its single-use and single-patient devices and components are used in a range of medical devices, disposable wound care products, infection prevention, minimally invasive surgery, wearables, orthopedic soft goods, and orthopedic implant packaging. The company also provides engineered products and components to customers in the automotive, aerospace and defense, consumer, electronics, and industrial markets, which are applied in military uniform and gear components, automotive interior trim, athletic padding, environmentally protective packaging, air filtration, abrasive nail files, and protective cases and inserts. It markets and sells its products in the United States principally through a direct sales force, as well as independent manufacturer representatives. The company was founded in 1963 and is headquartered in Newburyport, Massachusetts.

Analyst Sentiment

71%
Strong Buy

Based on 4 ratings

Analyst 1Y Forecast: $252.00

Average target (based on 2 sources)

Consensus Price Target

Low

$252

Median

$298

High

$344

Average

$298

Potential Upside: 47.2%

Price & Moving Averages

Loading chart...

๐Ÿ“˜ Full Research Report

โ„น๏ธ

AI-Generated Research: This report is for informational purposes only.

๐Ÿ“˜ UFP TECHNOLOGIES INC (UFPT) โ€” Investment Overview

๐Ÿงฉ Business Model Overview

UFP Technologies Inc. (UFPT) is a designer and custom manufacturer of component solutions primarily engineered from foam, plastics, and specialized materials. The company operates as a critical supplier across healthcare, medical device, automotive, aerospace & defense, and consumer product sectors. UFPTโ€™s core competency lies in its deep expertise in materials science, custom engineering, and managed production capabilities, allowing it to act as an extension of customersโ€™ R&D and supply chain functions. The business pursues a high-mix, low-volume manufacturing approach, focusing on complex, high-value-added products rather than commoditized mass production, positioning itself as a differentiated partner in industries where quality, regulatory compliance, and innovation are critical.

๐Ÿ’ฐ Revenue Streams & Monetisation Model

UFPT derives revenue from the design, engineering, and manufacturing of custom components and packaging solutions. Its primary business segments include:
  • Medical & Healthcare: Supplying sterile and non-sterile packaging, single-use components, and assemblies for medical devices, pharmaceuticals, and diagnostics. This segment is characterized by long customer relationships, high regulatory demands, and repeat purchasing cycles.
  • Automotive & Aerospace: Providing protective packaging, insulation, and interior components for vehicles and aircraft, often through just-in-time manufacturing. Contracts in these sectors can be multi-year in duration with large OEMs and Tier-1 suppliers.
  • Consumer & Industrial: Serving brands needing custom packaging or product components for high-end electronics, appliances, and niche industrial applications.
The company's monetization model is predominantly B2B, structured around contractual manufacturing orders, multi-year supply agreements, and in some cases, strategic partnerships or vendor-managed inventory arrangements. Revenue stability is enhanced by UFPTโ€™s embedded status in customer supply chains, creating recurring revenue profiles.

๐Ÿง  Competitive Advantages & Market Positioning

UFPTโ€™s competitive edge rests on a blend of technical expertise, regulatory know-how, and advanced manufacturing capabilities. Key elements include:
  • Diversification: Broad end-market exposure reduces dependency on any single industry or client.
  • Engineering Depth: Advanced materials science and engineering enable solutions that meet stringent customer specifications, particularly in highly regulated fields like healthcare.
  • Regulatory Qualification: Certification and experience in FDA, ISO, cGMP, and other standards allow access to sensitive markets inaccessible to less sophisticated peers.
  • Sticky Customer Relationships: High switching costs, including regulatory re-qualification and engineering validation, create a durable competitive moat.
  • Operational Footprint: Multiple manufacturing locations across North America enhance regional responsiveness and supply chain resilience.
The company is often selected as a sole or preferred supplier for mission-critical components, giving it an entrenched position with numerous blue-chip customers.

๐Ÿš€ Multi-Year Growth Drivers

UFPT is positioned to capitalize on several durable growth levers:
  • Healthcare and Medical Device Tailwinds: Demographic trends, innovation in minimally invasive surgery, diagnostics, and single-use devices increase demand for sophisticated packaging and component solutions.
  • Outsourcing of Design & Manufacturing: OEMs and brands continue to outsource complex, non-core component manufacturing to specialized partners like UFPT, given the need for compliance and nimbleness in design iteration.
  • Expansion into Higher-Margin Segments: Growth in medical and life sciences, compared to legacy industrial markets, enhances overall profitability and top-line expansion.
  • Strategic Acquisitions: Management has a track record of disciplined M&A to augment manufacturing capabilities, broaden the material portfolio, and access new customers and verticals.
  • Innovation in Materials Science: Ongoing development of sustainable, advanced, and sterile-ready materials opens incremental market opportunities, especially as sustainability regulations and preferences accelerate.

โš  Risk Factors to Monitor

Despite robust growth potential, UFPT faces salient business and industry risks:
  • Customer Concentration: A significant portion of revenue can be traced to a handful of large customers, especially in healthcare. Loss or consolidation among these customers could impact results.
  • Regulatory & Compliance Risks: Operating in regulated sectors exposes UFPT to compliance, inspection, and certification risk, with potential for costly delays or penalties.
  • Raw Material Volatility: Margins are subject to fluctuations in the cost and availability of specialized resins, foams, and plastics. Ability to pass through cost changes to customers may be limited.
  • Macro-Economic Sensitivity: While healthcare provides a stabilizing effect, exposure to cyclical markets like automotive and aerospace could pressure results during downturns.
  • Operational Complexity: Managing multiple sites, diverse production lines, and high-mix manufacturing increases the risk of execution missteps.

๐Ÿ“Š Valuation & Market View

UFPTโ€™s valuation reflects its leadership position in engineered packaging and component solutions, particularly in the high-growth medical and healthcare verticals. Investors typically afford UFPT a premium to peer industrials, owing to its above-average margins, diversified end-market exposure, and consistent track record of profitable growth. The company demonstrates high return on invested capital, strong free cash flow, and a conservative balance sheet with optionality for acquisitions. Market participants generally recognize its niche moat, but valuation may be sensitive to the pace of medical market penetration, visibility in the deal pipeline, and broader industrial sector sentiment. Earnings multiples, whether on an EBITDA or forward earnings basis, can trend toward the upper quartile among specialty manufacturers, justified by sustained double-digit sales growth and stable margin trajectories.

๐Ÿ” Investment Takeaway

UFP Technologies Inc. presents a compelling long-term investment case anchored by its entrenched customer relationships, diversified end-market exposure, and positioning at the confluence of healthcare innovation and advanced manufacturing. The transition toward higher-mix, regulated, and higher-margin segments, particularly within medical devices and life sciences, provides structural growth and a defensible competitive moat. While risks around customer concentration and operational complexity merit ongoing scrutiny, managementโ€™s disciplined execution, strong balance sheet, and adaptability to evolving market demands underpin an attractive risk-reward profile for investors with a multi-year horizon.

โš  AI-generated โ€” informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

๐Ÿ“Š AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"UFPT posted a total revenue of $148.9M with a net income of $17.6M and earnings per share (EPS) of $2.28. With total assets at $665.7M and total liabilities of $241.9M, the company demonstrates a solid equity position of $423.9M. Operating cash flow stands at $16.8M, and free cash flow is approximately $12.9M. The firm has not distributed any dividends. Currently, UFPT's stock price has decreased by approximately 9.94% over the past year, presenting a challenging market environment. With a price target consensus of $298 compared to its current price of $189.57, potential for recovery exists. However, the significant drop indicates potential market concerns about growth or operational effectiveness that need to be monitored."

Revenue Growth

Positive

Revenue of $148.9M shows solid growth, but further context is required.

Profitability

Neutral

Net income at $17.6M reflects profitable operations, but margins should be evaluated.

Cash Flow Quality

Fair

Positive free cash flow of $12.9M demonstrates good cash generation.

Leverage & Balance Sheet

Good

Strong equity position with manageable debt levels compared to assets.

Shareholder Returns

Neutral

No dividends paid, and negative price change may concern shareholder returns.

Analyst Sentiment & Valuation

Fair

Price target suggests upside potential despite current undervaluation.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Management sounded broadly bullish (robust pipeline, contract extensions through 2030/2026-2027, expanding capacity in the Dominican Republic, and improved AJR efficiency). However, the Q&A reveals two real operational constraints beneath that optimism: (1) AJR E-Verify labor inefficiency/backlogโ€”$6.3M full-year cost, with Q4 still a $1.2M headwind; overtime/backlog required, and Q1 is expected to take a hit (though less than Q4 and diminishing after). (2) A mid-quarter ransomware incidentโ€”operations were kept running via contingency plans and ERP restoration, but shipping/labeling delays were acknowledged; management expects no material Q1 impact overall, yet February softness with catch-up in March. Analysts pushed for concrete volume and backlog pacing, but customer confidentiality restricted specifics; only directional โ€œlow sevens minimumsโ€ were referenced for the largest customer and backlog is being worked down gradually through 2026.

AI IconGrowth Catalysts

  • Safe patient handling business: double-digit growth while making up prior backlog additions
  • Infection prevention: continued robust growth; new infection prevention program launched in La Romana (Building 5) with parts โ€œmaking partsโ€ and slow ramp
  • Robotic surgery: three new programs launched late (two robotic surgery + one infection prevention); additional robotic surgery capacity expansion planned via Dominican Republic Building 6
  • Contract extensions/expanded volumes with largest customer (material increase over current volumes; customers requested no public volume specificity)

Business Development

  • Largest customer contract extension: extended two additional years; expanded with an additional program (volumes increased materially but specifics withheld)
  • Largest infection prevention customer: contract extension funded through 2030
  • Market leader partnership in safe patient handling
  • Dominican Republic: new external capital program housed in La Romana Building 5; centralized warehouse supporting Buildings 1-4

AI IconFinancial Highlights

  • Full-year revenue: $602.8M (+19.5%); operating income +435% (2021-2025), EPS +419% (2021-2025)
  • 2025 EPS grew +15.4% despite absorbing $6.3M labor inefficiencies at Illinois AJR facility
  • AJR E-Verify labor inefficiency impact: $1.2M in Q4 vs $3.0M in Q3 (less than half), indicating onboarding/training progress
  • Gross margin: decreased to 28.3% in 2025 due to $6.3M extra labor costs; would have been 29.3% absent those costs
  • Adjusted operating margin: 17.1% of sales, within target 17%-20% despite extra labor costs
  • Effective tax rate: 17.2% for 2025, down from prior year; attributed to shift in pre-tax income to Dominican Republic (effectively pay no income taxes there)
  • Organic sales growth: low single digits for 2025; Ron cited abnormally high 2024 robotic surgery sales base and AJR safe patient handling backlog due to labor issue
  • Guidance impact detail: no explicit EPS/revenue guidance provided in transcript; Q1 expected to be impacted by AJR inefficiency, less than Q4 and diminishing after

AI IconCapital Funding

  • Cash from operations: ~$92.0M (2025)
  • Capital expenditures: $12.9M (2025)
  • Acquisitions: funded three acquisitions in 2025 (four in 2024 mentioned earlier)
  • Debt reduction: paid down ~$53.9M
  • Leverage ratio: ~1.1x (ended 2025)

AI IconStrategy & Ops

  • Illinois AJR: staffed up to needed level; transition from temps to permanent as skills reach threshold; still running overtime to knock down backlog; overtime expected to be reduced once backlog is worked down; Q1 has some impact, less than Q4, diminishing thereafter
  • Dominican Republic capacity expansion: Santiago launched second major program; negotiated lease for third building to expand safe patient handling and transfer third major program
  • La Romana Buildings 1-4: Building 5 move completed; houses expanded product development center, external capital program, and centralized warehouse
  • La Romana Building 6: planned possession in April; requires clean rooms/set-up before starting; intended to expand robotic surgery capacity to support anticipated growth
  • Program transfer pacing (AJR/customer programs): Program 1 completely transferred and running at rate; Program 2 transferred but not running at rate; Program 3 transfer scheduled after Program 2 completion and tied to April building possessionโ€”second-half-of-year assignment (capabilities redundant in Illinois; transfers expected to generate customer cost savings and additional UFPT profit potential at run-rate levels)
  • Cybersecurity operations continuity: ransomware attack hit mid-quarter; ERP systems back online during the call; contingency plan used to operate with manual invoicing and manual shipping/labeling delay

AI IconMarket Outlook

  • Safe patient handling / medtech growth: management expects robust growth in 2026; specifically referenced double-digit growth in safe patient handling and continued patient services market expansion
  • Q1 impact (AJR labor inefficiency): some impact expected in Q1, less than Q4; diminishing after; continued progress expected in each consecutive quarter
  • Cybersecurity: management stated no material impact expected on Q1 in its entirety; softness in February within Q1, with catch-up in March

AI IconRisks & Headwinds

  • Illinois AJR E-Verify labor inefficiencies (labor challenge): $6.3M extra labor costs in 2025; Q4 impact $1.2M; Q3 $3.0M; backlog carry-over into 2026; overtime needed until backlog worked down
  • Cybersecurity breach: ransomware attack detected Feb 14; data taken and destroyed; impacts included inability to label properly and ship everything day one; ERP systems restored; manual invoicing/shipping used during disruption
  • Organic sales growth headwinds: low single-digit organic growth due to abnormally high 2024 robotic surgery sales base and safe patient handling backlog caused by AJR labor issue
  • Backlog disclosure limitation: customer requested not to disclose backlog specifics; pacing described as gradual work-down throughout 2026

Sentiment: MIXED

Note: This summary was synthesized by AI from the UFPT Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
๐Ÿ“

SEC Filings (UFPT)

ยฉ 2026 Stock Market Info โ€” UFP Technologies, Inc. (UFPT) Financial Profile